Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1beta. 1997

K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
Rush Medical College at Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.

OBJECTIVE Recombinant human osteogenic protein 1 (OP-1) is an effective stimulator of human cartilage 35S-proteoglycan synthesis. The present study was conducted to determine whether stimulation of human articular chondrocytes with OP-1 can help overcome interleukin-1beta (IL-1beta)-induced suppression of 35S-proteoglycan synthesis. METHODS Human articular chondrocytes in alginate beads were maintained for 3 days in the absence (control) or presence of IL-1beta at 0.1-100 pg/ml with or without OP-1 at 50 ng/ml, in medium containing 10% fetal bovine serum (FBS). Incorporation of 35S-sulfate into proteoglycans was quantified during the last 4 hours of culture and reported as counts per minute per microg DNA. Release of interleukin-1 receptor antagonist (IL-1Ra) and prostaglandin E2 into the medium was monitored by immunoassay. RESULTS IL-1beta at 10 pg/ml caused a 60% decrease in 35S-proteoglycan synthesis. This could be blocked by including 500 ng/ml IL-1Ra in the medium. The presence of 50 ng/ml OP-1 in the IL-1beta-containing medium was effective in restoring 35S-proteoglycan synthesis to the level of that found in cultures not treated with IL-1beta. The restorative effects of OP-1 and IL-1Ra were cumulative. The rate of release of prostaglandin E2 and IL-1Ra into the medium was not affected by the presence of OP-1. CONCLUSIONS Treatment of human articular chondrocytes with OP-1 cultured in the presence of FBS is effective in overcoming the down-regulation of proteoglycan synthesis induced by low doses of IL-1beta.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002358 Cartilage, Articular A protective layer of firm, flexible cartilage over the articulating ends of bones. It provides a smooth surface for joint movement, protecting the ends of long bones from wear at points of contact. Articular Cartilage,Articular Cartilages,Cartilages, Articular
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
June 2002, The Tohoku journal of experimental medicine,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
January 2002, Arthritis research,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
April 2002, American journal of veterinary research,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
January 2009, Arthritis and rheumatism,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
February 1990, Biochemical and biophysical research communications,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
March 2007, BMC musculoskeletal disorders,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
January 1996, American journal of therapeutics,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
January 1993, Agents and actions,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
January 2009, Connective tissue research,
K Huch, and B Wilbrink, and J Flechtenmacher, and H E Koepp, and M B Aydelotte, and T K Sampath, and K E Kuettner, and J Mollenhauer, and E J Thonar
January 1999, Clinical and experimental rheumatology,
Copied contents to your clipboard!